# Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

- **DOI:** [10.1016/s2352-3026(24)00081-4](https://doi.org/10.1016/s2352-3026(24)00081-4)
- **Rating:** Sound (3.5 out of 5)
- **Verdict:** Long-term garadacimab follow-up adds clinically useful durability and tolerability evidence, but the uncontrolled open-label extension limits causal efficacy and HRQoL conclusions.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-25
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fs2352-3026(24)00081-4

## Key claims

1. Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL.
   - Support: Supported
   - Type: Primary finding
   - Basis: large sustained observed reductions, but uncontrolled open-label follow-up limits causal efficacy and HRQoL inference
   - Location: Summary, Interpretation, p e436
2. Median reduction in monthly attack rate versus run-in was 100% (IQR 98–100) with garadacimab 200 mg.
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported descriptive result, though the before–after extension design limits causal interpretation
   - Location: Summary, Findings, p e436; Results, p e442
3. HRQoL improvements observed during TP1 with garadacimab were sustained throughout TP2.
   - Support: Supported
   - Type: Secondary
   - Basis: longitudinal AE-QoL and WPAI patterns support persistence, but open-label patient reporting permits expectation effects
   - Location: Summary, Findings, p e436; Figure 3
4. TP2 safety signals were consistent with TP1.
   - Support: Supported
   - Type: Secondary
   - Basis: systematic adverse-event reporting supports consistency, while the small cohort cannot characterise uncommon harms
   - Location: Summary, Findings, p e436; Table 2

## Strengths

- **Long-duration evidence for monthly prophylaxis** TP2 provides attack-rate, quality-of-life, and tolerability observations over extended exposure, with treatment lasting as long as 129 weeks across the full study.
  - Dimension: contribution
  - Location: Research in context, p e437; Results, p e442
- **Transparent handling of dose transitions** The protocol-mandated reduction from 600 mg to 200 mg and the resulting overlapping dose-group assignments are explained in the Methods, trial profile, and table and figure notes.
  - Dimension: methodological rigour
  - Location: Methods, pp e439–41; Figure 1; Table 1
- **Systematic long-term harms reporting** Adverse events were coded, graded, exposure-adjusted, and reported alongside prespecified events of special interest, with independent safety-board oversight.
  - Dimension: methodological rigour
  - Location: Methods, pp e439–41; Table 2

## Limitations

- **No concurrent control during long-term follow-up** TP2 used an open-label, uncontrolled design with descriptive analysis only, so sustained attack-rate and HRQoL observations cannot independently establish long-term causal efficacy.
  - Dimension: methodological rigour
  - Location: Methods, pp e438–40; Discussion, p e445
- **Subjective outcomes remain expectation-sensitive** AE-QoL, WPAI, SGART, and IGART were collected while participants and investigators knew active treatment was being received, without a reported mitigation strategy.
  - Dimension: methodological rigour
  - Location: Outcomes, pp e439–40; Discussion, p e445
- **Small and demographically narrow cohort** The extension included 38 adults, 87% of whom were White, limiting transferability and the ability to characterise uncommon harms.
  - Dimension: application pathway
  - Location: Table 1, p e441; Discussion, p e445

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Clean. Participant flow, overlapping dose-group denominators, protocol-mandated down-titration, and adverse-event totals are internally consistent and transparently explained. No statistical impossibility or material methods–results mismatch was identified.
- **Research conduct:** Noted. Ethics approval, consent, prospective registration, conflicts, and sponsor roles are disclosed. The sponsor's direct participation in study design, data collection, analysis, interpretation, manuscript review, and funded medical writing is a disclosed structural consideration.
- **Reference integrity:** Clean. 25 of 25 checkable references verified
  - 25 references in manuscript
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
